| Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis ZD Nagel, CM Margulies, IA Chaim, SK McRee, P Mazzucato, A Ahmad, ... Proceedings of the National Academy of Sciences 111 (18), E1823-E1832, 2014 | 136 | 2014 |
| Genome-wide single-cell-level screen for protein abundance and localization changes in response to DNA damage in S. cerevisiae A Mazumder, LQ Pesudo, S McRee, M Bathe, LD Samson Nucleic acids research 41 (20), 9310-9324, 2013 | 51 | 2013 |
| AKT1 is required for a complete Palbociclib-Induced Senescence phenotype in BRAF-V600E-Driven Human Melanoma AL Bayer, J Pietruska, J Farrell, S McRee, P Alcaide, PW Hinds Cancers 14 (3), 572, 2022 | 6 | 2022 |
| AKT2 loss impairs BRAF mutant melanoma metastasis SK McRee, JR Pietruska, PN Tsichlis, PW Hinds Cancer Research 78 (13_Supplement), 1112-1112, 2018 | 3* | 2018 |
| Genomic phenotyping by barcode sequencing broadly distinguishes between alkylating agents, oxidizing agents, and non-genotoxic agents, and reveals a role for aromatic amino … JP Svensson, L Quirós Pesudo, SK McRee, Y Adeleye, P Carmichael, ... Plos one 8 (9), e73736, 2013 | 3 | 2013 |
| Abstract PR14: Defining isoform-specific roles for AKTs in BRAFV600E-driven melanoma J Farrell, J Pietruska, S McRee, P Tsichlis, P Hinds Cancer Research 80 (19_Supplement), PR14-PR14, 2020 | 1 | 2020 |
| ORIC-613, a potential first-and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models KA Edgar, S McRee, G Andretta, C Chen, C Colas, W Fang, W Kong, ... Cancer Research 84 (6_Supplement), 594-594, 2024 | | 2024 |
| Selective PLK4 Inhibitors Demonstrate Synthetic Lethality in TRIM37 Amplified Neuroblastoma and Breast Cancer Models While Less Selective Inhibitors Do Not SK McRee, X Chen, C Colas, A Daemen, W Fang, W Kong, J Long, F Liu, ... | | 2023 |
| Defining isoform-specific roles for AKTs in BRAF (V600E)-driven melanoma. J Farrell, J Pietruska, S McRee, P Tsichlis, P Hinds CANCER RESEARCH 80 (19), 29-30, 2020 | | 2020 |
| Functional analysis and therapeutic targeting of AKT isoforms in BRAF mutant melanoma SK McRee Tufts University-Graduate School of Biomedical Sciences, 2018 | | 2018 |
| Abstract B07: Differential roles for AKT isoforms in BRAF mutant melanoma SK McRee, JR Pietruska, E Dignan, PW Hinds Clinical Cancer Research 23 (1_Supplement), B07-B07, 2017 | | 2017 |
| Using High-Throughput Assays to Measure Interindividual Differences in DNA Repair Capacity and to Understand Mechanisms of Cancer Therapy Resistance. ZD Nagel, CM Margulies, IA Chaim, SK McRee, P Mazzucato, A Ahmad, ... ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 55, S35-S35, 2014 | | 2014 |
Mark BatheBiological Engineering, MITVerified email at mit.edu
